Infographic summarizing the Nature mouse study: older mice given daily semaglutide ate about 24 percent less and had a median lifespan of 834 days versus 742 days, with human lifespan trials, small doses and effects beyond eating less all still unanswered.

Semaglutide Extended Mouse Lifespan. It Was Not a Microdose Study.

November 12, 2026

Short answer: A September 2026 study in Nature found that daily semaglutide extended the median lifespan of old female mice from 742 to 834 days, about 12 percent. The dose was large enough to cut food intake by 24 percent, so it was a full pharmacologic dose and not a microdose. No human lifespan data exist, and the study cannot say whether the effect goes beyond eating less.

Ask PeptideBlog about any peptide

Research snapshot (as of Nov 12, 2026)

CategoryCurrent information
StudyFeng et al., Nature 657(8131):469-476, published Sept 2, 2026 (DOI)
Evidence tierTier 3: published animal evidence
Species and sexFemale C57BL/6 mice, treatment started at 20 months old
Human dataNone on lifespan or aging
Microdosing testedNo
Regulatory statusSemaglutide is approved for diabetes and weight management. Nothing is approved for slowing aging.
Last reviewedNovember 12, 2026

What the study actually tested

The corresponding author is Danica Chen at UC Berkeley, and the paper appeared in Nature on September 2, 2026. According to the NIH release, the work was NIH funded. The authors treated old female mice with semaglutide and followed them in three ways: a lifespan group, a three-month function cohort, and a separate comparison against calorie restriction.

Design elementWhat the paper reports
AnimalsFemale C57BL/6 mice from the National Institute on Aging, starting at 20 months old. Females were used to avoid injuries from male fighting.
Drug and routeSemaglutide, 10 nmol/kg, one subcutaneous injection daily
Effect on eatingFood intake fell by 24 percent, with lower body weight and fat mass
Lifespan arm39 saline mice vs 40 semaglutide mice, treated until death
Lifespan resultMedian 742 days (saline) vs 834 days (semaglutide), about 12 percent longer
Function cohortSeparate three-month cohort, with tests of open-field activity, Barnes maze, rotarod, inverted screen, treadmill and glucose tolerance
Calorie restriction comparisonSeparate cohort, 10 mice per group, 5 months, restriction matched to the 24 percent drop in intake. No lifespan group.
SafetyNo adverse effects attributable to semaglutide in the endpoints the authors monitored

The amount is shown in the units the paper used, for a mouse. It has not been converted to a human amount, and this page does not give one. Mouse metabolism and drug handling differ from ours, and crude scaling would be a guess presented as a number.

What it found

  • Lifespan: semaglutide-treated mice lived longer, with median survival of 834 days against 742 days on saline. The exact test result is in the paper’s figure.
  • Function: in the three-month cohort, treated mice did better on the movement, memory, strength and glucose tests listed above, with lower markers of inflammation and cell senescence, higher NAD+ and lower IGF1.
  • Against calorie restriction: many outcomes were comparable. Semaglutide did better on open-field centre time, Barnes maze and glucose tolerance.
  • Authors’ framing: they call semaglutide a calorie restriction mimetic, and say that whether it slows aging or extends lifespan in people needs long-term clinical studies.

In plain terms, this is a well-run mouse study that points the same way as calorie restriction research. It is one study in one sex of one strain, and its own authors say the human question is open.

Claims people make versus what this study tested

Claim you may seeWhat the study testedVerdict
Semaglutide extends lifespanFemale mice, 39 vs 40, daily injection from 20 monthsSupported in this mouse model only
Microdosing GLP-1 helps you live longerA dose that cut food intake by 24 percentNot tested. This was not a low dose.
It works independently of calories or weight lossLifespan arm had no calorie-restricted group. The physiology comparison was 10 mice per group over 5 months.Not shown for lifespan. Some physiology measures differed from calorie restriction.
It reverses agingBetter scores on some function tests and lower aging markersOverstated. The authors raise the possibility of reversing decline in some measures only.
It works in people, or in menFemale mice onlyNot tested. The authors call for long-term clinical studies.
It is safe long termNo attributable adverse effects in monitored endpoints in miceNarrow, and not a human safety finding

The calorie restriction problem

Calorie restriction is the best-known way to extend lifespan in lab animals. The headline question is whether semaglutide does something more than make animals eat less.

The paper gives a partial answer. In the separate five-month cohort, restriction was matched to semaglutide’s 24 percent drop in intake, and the two groups looked alike on many outcomes. Semaglutide came out ahead on three: open-field centre time, Barnes maze performance and glucose tolerance. The abstract says this reveals effects beyond those attributable to reduced calorie intake.

That conclusion rests on a small physiology comparison. There were 10 mice per group, the follow-up was five months, and nobody tracked survival in the calorie-restricted animals. So the study does not show that semaglutide lengthens life by a route other than eating less, and a reader who needs that answer should treat it as open.

Is there a low-dose aging study?

Yes, and it is a different experiment. A Hong Kong team at the Chinese University of Hong Kong published in Cell Metabolism on November 19, 2025 (DOI). They treated aged male mice with a GLP-1 receptor agonist from 11 months of age for 30 weeks. The abstract says the dose was relatively low and minimally affected food intake or body weight. The paper lists exenatide among its keywords.

FeatureFeng et al., Nature 2026Huang et al., Cell Metabolism 2025
DrugSemaglutideA GLP-1 receptor agonist (exenatide is a listed keyword)
SexFemaleMale
Dose effectCut food intake by 24 percentMinimal effect on food intake or body weight
Main readoutsLifespan, function tests, aging markersMulti-omic aging signatures and selected physical functions
Lifespan reportedYes, in miceNot in the abstract
Evidence tierTier 3: animalTier 3: animal

Taken together, one mouse study found a lifespan effect at a full dose, and another found molecular changes at a low dose in a different drug and sex. Neither tested microdosing in people, and neither shows that a low dose extends life.

The human evidence gap

  • No randomized trial tests GLP-1 drugs for lifespan or for slowing aging in humans.
  • PB’s semaglutide dosage page found no label, randomized trial or registered trial that supports microdosing. The main study it identified is observational, in people who kept filling 0.25 mg prescriptions.
  • Cardiologist Eric Topol called microdosing a craze that is not substantiated, and Daniel Drucker said there is no consensus on what a microdose is, both as reported by The Independent in September 2025 from a Washington Post story.
  • Lilly told The Independent that splitting doses of Zepbound and Mounjaro is not covered by the FDA label and may carry safety risks. That statement is about Lilly’s products, not semaglutide.

For where these drugs sit in practice, see PB’s piece on off-label and lifestyle use of GLP-1 drugs. Treated mice lost fat mass along with weight, which raises the human question of what happens to muscle. That is covered in what happens to muscle when GLP-1 drugs get more powerful.

What circulates online versus what studies used

Online discussion of GLP-1 microdosing uses a range of fractions and schedules, and there is no agreed definition of the term. No established or reliably sourced dosing information for lifespan or longevity use was identified, and this page does not offer any. The only longevity-related amount in the literature reviewed here is the mouse figure above, which is not a human amount.

SourceWhat it usedEvidence class
Feng et al., Nature 202610 nmol/kg daily in mice, a dose that cut intake by 24 percentPublished animal research
Huang et al., Cell Metabolism 2025A relatively low dose of a GLP-1 agonist in male mice, with minimal effect on intake or weightPublished animal research
Online microdosing discussionsVaried, with no shared definitionCommunity reported, no identifiable original source

Limits of this analysis

  • This page used the paper’s text and the abstract. The competing interests statement, extended data figures and peer review file were not read.
  • The statistical value for the lifespan comparison sits in a figure and is not quoted here.
  • The calorie restriction comparison is physiology only. A matched calorie-restriction lifespan group does not exist in this paper.
  • The Huang et al. summary comes from its abstract.
  • Press quotes are secondary sources. They are included to show the range of expert caution, not as evidence.

Frequently asked questions

Does semaglutide extend life?

In one mouse study, yes: old female mice lived about 12 percent longer on median. No study has shown it in people.

Does microdosing GLP-1 help you live longer?

Not tested. The mouse study used a dose that reduced food intake by 24 percent, and PB found no label, randomized trial or registered trial that supports microdosing.

Was the semaglutide lifespan study done in humans?

No. It used female C57BL/6 mice that were 20 months old at the start.

Is semaglutide a calorie restriction mimetic?

The authors describe it that way. Their calorie-restriction comparison was a five-month physiology study, so it does not settle the question for lifespan.

What dose of semaglutide was used in the mouse study?

The paper used 10 nmol/kg by daily subcutaneous injection in mice. That is a mouse figure and not a human amount.

Has anyone studied low-dose GLP-1 and aging?

A Cell Metabolism paper from Hong Kong tested a relatively low dose of a GLP-1 agonist in aged male mice and reported molecular aging effects. It did not report lifespan in its abstract.

Bottom line

The semaglutide lifespan result is real, and it is a mouse result. It came from a full pharmacologic dose in old females, and it cannot show that microdosing does anything. The calorie restriction question is partly answered for physiology and unanswered for lifespan. The human question needs trials that do not yet exist. PB found no reliable dosing information for longevity use, and everything online beyond the mouse figures is unverified.

Sources

SourceAuthors or organizationPublicationDateCategory
Late-life semaglutide treatment slows ageing and extends lifespan in female miceFeng Y et al.Nature 657(8131):469-476Sept 2, 2026Published animal research
Body-wide multi-omic counteraction of aging with GLP-1R agonismHuang J et al.Cell Metab 37(12):2362-2380Nov 19, 2025Published animal research
GLP-1 treatment late in life extends lifespan in animal modelNational Institutes of HealthNIH news releaseSept 2026Institutional release
Scientists say there is no link between microdosing weight-loss drugs and living longerThe Independent, citing the Washington PostNews report via YahooSept 4, 2025News, expert commentary

Update history: November 12, 2026, first version.

Share thisFacebookXEmail
Image placeholder

PeptideBlog Editorial compiles and reviews published research, clinical trial data, and community-reported information on peptides so readers can see what is actually documented versus what is simply repeated online. Every entry is sourced and evidence-graded. This is educational content, not medical advice.